NICE wants more Soliris information

The United Kingdom's price watchdog wants to know why Alexion's rare disease-drug, Soliris, costs so much. PharmaLive reports that the agency wants to know what the company spends on manufacturing and R&D as part of its review process.

The rare-disease medication treats the inflammatory condition atypical hemolytic uremic syndrome and is available in the UK under a special agreement that allows it to be used prior to approval.

The drug costs around $200,000, per patient, per year in the US, and the regulator expects the drug would cost around $96,000 for the first year on its formulary, only to rise to $133,000 in five years.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.